Caricamento...
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
The harnessing in clinical practice of cyclin-dependent kinases 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, has substantially changed the therapeutic approach for hormone receptor-positive metastatic breast cancer (BC). Phase II–III clinical trials evaluating the addition of the...
Salvato in:
| Pubblicato in: | NPJ Breast Cancer |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6715721/ https://ncbi.nlm.nih.gov/pubmed/31482107 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-019-0121-y |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|